# OEA and LipiSperse Metabolic Study

> **NCT06840080** · PHASE4 · COMPLETED · sponsor: **RDC Clinical Pty Ltd** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers - Male and Female
- Pharmacokinetic Study in Healthy Volunteers

## Interventions

- **OTHER:** Placebo
- **DIETARY_SUPPLEMENT:** 125mg OEA with LipiSperse
- **DIETARY_SUPPLEMENT:** 250mg OEA with LipiSperse

## Key facts

- **NCT ID:** NCT06840080
- **Lead sponsor:** RDC Clinical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-04
- **Primary completion:** 2025-06-04
- **Final completion:** 2025-06-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840080, "OEA and LipiSperse Metabolic Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06840080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*